UFT Plus or Minus Calcium Folinate for Metastatic Golorectal Cancer in Older Patients

ONCOLOGY

Volumn 13, Issue 7 SUPPL., 1999, Pages 35-40

  Díáz Rubio, Eduardo ^a   Sastre, Javier ^a   Abad, Albert ^b   Navarro, Matilde ^c   Aranda, Enrique ^d   Carrato, Alfredo ^e   Gallen, Manuel ^f   Marcuello, Eugenio ^g   Rifá, Julio ^h   Massuti, Tomeu ⁱ   Cervantes, Andrés ^j   Antón, Antonio ^k   Martos, Carlos Fernández ^l  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h Hospital San Dureta   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^l INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOLINATE CALCIUM; METHOTREXATE; TEGAFUR; URACIL;

ADVANCED CANCER; AGED; ALOPECIA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG HALF LIFE; DRUG INFUSION; DRUG MIXTURE; ELDERLY CARE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PROGNOSIS; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0032813746     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Piedbois P, Buyse M, Rusum Y, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
2. Piedbois P, Buyse M, Blijham G, et al: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960-969, 1994.
3. Abad A, Garcia P, Gravaios C, et al: Sequential methotrexate, 5-fluorouracil (5-FU) and high-dose leucovorin versus 5-FU and high-dose leucovorin versus 5-FU alone for advanced colorectal cancer. Cancer 75:1238-1244, 1995.
4. Aranda E, Díáz-Rubio E, Cervantes A, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with high-dose 48-hour continuous infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 9:727-731, 1998.
5. The Meta-analysis Group in Cancer: Efficacy of intravenous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998.
6. Fentiman S: Are the elderly receiving appropriate treatment for cancer? Ann Oncol 7:657-658, 1996.
7. Monfardini S, Chabner B: Joint NCI-EORTC Consensus meeting on neoplasia in the elderly. EurJ Cancer 27:653-654, 1991.
8. Watanabe H, Yamamoto S, Naito T: Clinical results of oral UFT therapy under cooperative study. Gan To Kagaku Ryoho 7:1588-1596, 1980.
9. Murakami M, Ota K: Clinical results of UFT therapy for malignant tumors under cooper- ative study. Gan To Kagaku Ryoho 7:1579-1586, 1980.
10. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333-338, 1998.
11. Malik STA, Talbot D, Clarke PI, et al: Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 62:1023-1025, 1990.
12. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296-2300, 1994.
13. Pazdur R: Phase II study of UFT plus leucovorin in colorectal cancer. Oncology 54(suppl 1):19-23, 1997.
14. Gonzalez Baron M, Feliu J, de la Gandara I, et al: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer: A phase II study. Eur J Cancer 31:2215-2219, 1995.
15. Díáz-Rubio E, Aranda E, Camps C, et al: A phase II study of weekly 48 hours infusion with high-dose fluorouracil in advanced colorectal cancer: An alternative to biochemical modulation. J Infus Chemother 4:58-61, 1994.
16. Aranda E, Cervantes A, Dorta J, et al: A phase II trial of weekly high-dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. Cancer 76:559-563, 1995.
17. Aranda E, Cervantes A, Carrato A, et al: Outpatient weekly high-dose continuous infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer: A phase II trial. Ann Oncol 7:581-585, 1996.
18. Díáz-Rubio E, Aranda E, Martin M, et al: Weekly high-dose infusion 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 26:727-729, 1990.
19. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 40:207-214, 1981.
20. Feliu J, Gonzalez Baron M, Espinosa E, et al: Uracil and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 10:1884-1889, 1997.